←
Simone Hausmann107 posts
Simone Hausmann avatar

Simone Hausmann

@Simone_Hausmann

Instructor at MD Anderson Cancer Center - Pancreatic and Lung Cancer. Interested in drug resistance mechanisms

◷ Joined December 2013▧ 3 Photos and videos
Sebastian S. Cocioba🪄🌷 avatar
⟳ Simone Hausmann retweeted
Sebastian S. Cocioba🪄🌷@ATinyGreenCell·2 May 2025

I got hit by some rather sudden and extreme financial hardship so if anyone is in need of remote wetlab contract research, strictly BSL1, do let me know. Currently scrambling for gigs. Plant, Bacterial, Archaeal Bioeng Custom Lab Hardware Turn Key Genetic Design Please RT 💚

CrozrX avatar
⟳ Simone Hausmann retweeted
CrozrX@CrozrX·3 Jan 2025

Increased KRAS mutant allele dosage is an important negative prognostic feature that will need to be integrated into clinical practice as we move into the era of 🎯 RAS-directed therapeutics for PDAC. 🔸️ Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival 🔸️ doi.org/10.1038/s41591-024-0…

Post attachmentPost attachmentPost attachmentPost attachment
Justin Manning ⓥ avatar
⟳ Simone Hausmann retweeted
Justin Manning ⓥ@justinmanningv·21 Nov 2024

My mom is dying from pancreatic cancer. She’s only 65. She’s my best friend outside my wife and daughter. I’m in the hospital with her right now (she’s sleeping) as I write this. She’s been in the hospital for almost the last two months.

David C Whitcomb MD PhD avatar
⟳ Simone Hausmann retweeted
David C Whitcomb MD PhD@DavidCWhitcomb·1 Dec 2023

#PancreaticCancer & #ArtificialInteligence. Cao et.al. published a paper in Nature (20Nov23 online) claiming an (AUC) of 0.986–0.996 for detection of pancreatic lesions including adenocarcinoma (#PDAC) using non-contrast CT. BUT, there is a BIG problem. (flow me for the answers) The training and testing was in cohorts with very high rates of known pancreatic cancers and known lesions. In "real" real world testing of the general population, where the incidence of occult pancreatic cancers is <0.001, the false positive rate would be huge compared to true positive (see PMID: 14731128 as an example). The key is to screen for occult PDAC in patients with a high risk for pancreatic cancer (PMID: 35704792) and with early signs and symptoms (PMID: 35065983). The new PANDA tool will fail as a CT screening tool for detection of occult PDAC in a general population. The utility will likely be as an aid to radiologist that are not experts at reading a non-contrast CT of the pancreas. Period. The solution to the stratification problem of defining high, and very high risk sub-populations will be discussed later. Stay tuned to @davidcwhitcomb . nature.com/articles/s41591-0… Note: PMID is the PubMed number on the ncbi.nlm.nih.gov web site. @PanCAN @NatPancFdn @UPMC @lustgartenfdn @PancPathologist @Aiims1742 @ArielMedicine #pancreatitis #deeplearning #DigitalHealth #PrecisionMedicine @AmCollegeGastro @PittGILiverNutr @GIPapachristou

KenOliveLab avatar
⟳ Simone Hausmann retweeted
KenOliveLab@KenOliveLab·6 Dec 2023

We are excited to share our preprint on the effects of RAS-GTP inhibition in preclinical models of PDAC, using RMC-7977, a potent inhibitor of GTP-bound RAS proteins. This preclinical agent is related to RMC-6236, currently in clinical trials. biorxiv.org/content/10.1101/…

EMBL Events avatar
⟳ Simone Hausmann retweeted
EMBL Events@EMBLEvents·3 Apr 2023

'Measuring translational dynamics by ribosome profiling' finished last Saturday and we can't believe how quickly it went by! 🥼🔬☕ Thanks to our organisers, trainers, and speakers 🙏🏻 and course participants who joined us for the whole week of science and fun! 👏 #EMBORiboProf

Post attachment